p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 3, 2010, Pages 859-868

  Anderson, Karen S ^a,b   Wong, Jessica ^a   Vitonis, Allison ^b   Crum, Christopher P ^b   Sluss, Patrick M ^c   LaBaer, Joshua ^d   Cramer, Daniel ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; HE4; P53 AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AREA UNDER CURVE; AUTOANTIBODIES; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949661790     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0880     Document Type: Article

References (53)

1. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005;4:1123-33.
2. Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 2003;52:715-38.
3. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
4. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007;18: 868-73.
5. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007;104: 17494-9.
6. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006;66:1181-90.
7. Gagnon A, Kim JH, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008;14:764-71.
8. Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008;7:1490-9.
9. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
10. Sangrajrang S, Arpornwirat W, Cheirsilpa A, et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 2003;27:182-6.
11. Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24:762-8.
12. Leffers N, Lambeck AJ, de Graeff P, et al. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecol Oncol 2008;110: 365-73.
13. Tsai-Turton M, Santillan A, Lu D, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009;114:12-7.
14. Using custom protein microarrays to identify autoantibody biomarkers for the early detection of breast cancer. In: Anderson KS, Sibani S, Wong J, et al, editors. San Antonio Breast Cancer Symposium, San Antonio (TX). 2008.
15. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
16. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35.
17. Ho ES, Lai CR, Hsieh YT, et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol 2001;80:189-93.
18. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003;97:389-404. 19. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003; 21:285-91.
19. Badgwell D, Bast RC, Jr. Early detection of ovarian cancer. Dis Markers 2007;23:397-410.
20. Mann WJ, Patsner B, Cohen H, Loesch M. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst 1988;80:208-9.
21. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. Jama 1993;269:1123-6.
22. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2872-81.
23. Zhang Z, Yu Y, Xu F, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107:526-31.
24. Nolen B, Marrangoni A, Velikokhatnaya L, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol 2009; 112:47-54.
25. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785-93.
26. Palmer C, Duan X, Hawley S, et al. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 2008;3: e2633.
27. Zheng Y, Katsaros D, Shan SJ, et al. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 2007;13:6984-92.
28. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res 2007;13:4422-8.
29. Terry KL, Sluss PM, Skates SJ, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004;20: 53-70.
30. Vang R, Shih Ie M, Salani R, Sugar E, Ayhan A, Kurman RJ. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 2008;32:1667-74.
31. Mayerhofer K, Tempfer C, Kucera E, et al. Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 1999;19:875-8.
32. Gadducci A, Ferdeghini M, Buttitta F, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999;72:76-81.
33. Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000;88:1432-7.
34. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
35. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996;78:2146-52.
36. Vogl FD, Stickeler E, Weyermann M, et al. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 1999;57:324-9.
37. Green JA, Robertson LJ, Campbell IR, Jenkins J. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: Correlation with differentiation. Cancer Detect Prev 1995; 19:151-5.
38. Angelopoulou K, Yu H, Bharaj B, Giai M, Diamandis EP. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 2000; 33:53-62.
39. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
40. van der Zee AG, Hollema H, Suurmeijer AJ, et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-8.
41. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76: 1201-8.
42. Bartel F, Jung J, Bohnke A, et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008;14:89-96.
43. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004;14: 1086-96.
44. de Graeff P, Hall J, Crijns AP, et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 2006;95:627-33.
45. Lambeck A, Leffers N, Hoogeboom BN, et al. P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. Int J Cancer 2007;121: 606-14.
46. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
47. Morgan AW, Robinson JI, Barrett JH, et al. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther 2006;8:R109.
48. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc ? receptor II is critical for human IgG2 binding. J Immunol 1991;147: 1338-43.
49. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
50. Laine M, Jarva H, Seitsonen S, et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007;178:3831-6.
51. Role of host immune response genes in the clinical response to trastuzumab-based therapies. In: Anderson KS AD, Keung E, Keshaviah A, et al, editors. San Antonio Breast Cancer Symposium, San Antonio (TX). 2006.
52. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-7.
53. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.